

Science Café

Team

Clinical Development in Challenging Cancers: Ovarian Clear Cell Carcinoma (OCCC)

In this issue of our newsletter, you can read more about Clinical Development in Challenging Cancers. This is our third article in the series of articles regarding rare types of cancer. Our Medics take a closer look at treatment, therapeutic challenges and Clinical Development in Ovarian Clear Cell Carcinoma (OCCC):

“Ovarian clear cell carcinoma (OCCC) is a rare histological subtype of epithelial ovarian cancers (EOCs), with an incidence, among EOCs, of 4-12% in Western countries [1-3] and a higher ratio of over 20% in Japan [4,5]. Histologically, EOCs are classified into serous, mucinous, endometrioid, clear cell and undifferentiated subtypes. Ovarian cancer is already the leading cause of death among gynecological malignancies in the US [6], in addition, the OCCC subtype presents a lower response rate to traditional platinum-based chemotherapy and is generally associated with poorer prognosis across all stages compared to other EOC subtypes [2,4,7-9...]”

We invite you to read the entire article (pages 42-47) by clicking at the following image:



It is our pleasure to introduce Dr. David Bruce our newly appointed Business Development Manager. With his strong scientific knowledge and significant experience in Business Development, David will be a driving force for strengthening Europital's position as a distinguished expert in the Medical Management of Clinical Research Projects. David will also support our continuous effort in further developing the excellent relationship between Europital and our Global clients in the pharmaceutical sector.

Welcome to the team
David!

Outdoor

Europital attended 2018 "Perspectives on Oncology Drug Discovery; Immuno-Oncology and the Next Generation" Symposium

Europital attended the symposium of "Perspectives on Oncology Drug Discovery; Immuno-Oncology and the Next Generation" held in the Cambridge Building, Babraham Research Campus, in Cambridge, UK on the 15th of March 2018.



"Immuno-oncology has revolutionised cancer research, with many novel agents already clinically approved. With continued enhancement of preclinical models and methods, the next generation of immunotherapeutics including combination therapies and new modalities can continue to bring patient benefits. The symposium brought together both oncology and immuno-oncology R&D and preclinical teams from industry, academia, and medical research to facilitate cross discipline discussions on current techniques, and how to move forward with future approaches."


Our Business Development Manager, David Bruce, PhD, MBA, attended this enriching symposium where he had a lot of valuable interactions with scientists and industry experts contributing to bringing new treatment options for patients in need.

Misc.

JOIN OUR TEAM

Europital is looking for new team members both in Gent and in our new offices in Budapest. Those who are interested in joining one of the most dynamic teams in the life science industry and looking to utilize their knowledge in building a successful career, are welcome to apply through our careers page on our website <https://europital.com/careers/>

Currently, we have fantastic opportunities for Clinical Research Physicians and for an Experienced Business Development Manager.



Copyright © 2018 Europital, All rights reserved.

Our mailing address is: info@europital.com
[unsubscribe from this list](#) [update subscription preferences](#)

